Wet AMD 6 mg intravitreal inj every 4 wk for 1st 3 doses, then individualize treatment intervals based on disease activity. DME 6 mg intravitreal inj every 6 wk for 1st 5 doses, then individualize treatment intervals based on disease activity. Patient w/o disease activity Treatment every 12 wk, patient w/ disease activity Treatment every 8 wk.
Discontinue use in patients w/ rhegmatogenous retinal detachment or stage 3 or 4 macular holes. Not to be inj while IOP is ≥30 mmHg. Endophthalmitis; intraocular inflammation including retinal vasculitis &/or vascular occlusion; traumatic cataract; retinal detachment & tear. Risk factors for retinal pigment epithelial tears. History of stroke, transient ischaemic attacks or MI w/in last 3 mth; poorly controlled glaucoma; diabetic patients w/ HbA1c >10% or proliferative diabetic retinopathy; uncontrolled HTN. Withhold & not to be resumed earlier than the next scheduled treatment in case of decrease in best-corrected visual acuity of ≥30 letters compared w/ last visual acuity assessment; retinal break; subretinal haemorrhage involving centre of fovea or if size of haemorrhage is ≥50% of total lesion area; performed or planned intraocular surgery w/in previous or next 28 days. Immunogenicity. Bilateral treatment. Monitor & manage for increased IOP & optic nerve head perfusion. Japanese patients. Not to be used concurrently w/ other systemic or ocular anti-VEGF medicinal products. May affect ability to drive or use machines. Hepatic impairment. Women of childbearing potential should use effective contraception during & for at least 1 mth after last dose. Not to be used during pregnancy. Not recommended during lactation & for at least 1 mth after last dose. Childn & adolescents <18 yr.
Sign Out
